GlassScriptPhysician profile
Susan Harrison
NPI 1942286117
$6,429.87
in general payments reported to CMS, 2019-2025
50 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $556 · 2022: $823 · 2023: $1,412 · 2024: $1,489 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,883 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,882.59 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,099.56 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $488.69 | 2021-2025 | Enhertu |
| Abbvie INC. | $477.63 | 2022-2025 | |
| Incyte Corporation | $456.26 | 2021-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $428.49 | 2021-2025 | Opdivo, Eliquis |
| Janssen Biotech, INC. | $398.45 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Glaxosmithkline, LLC. | $276.30 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $266.24 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Karyopharm Therapeutics INC. | $221.09 | 2022-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $198.41 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $179.10 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $151.91 | 2024-2025 | |
| Pfizer INC. | $118.95 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $117.11 | 2024-2025 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $110.75 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $108.56 | 2024 | |
| Beigene USA, INC. | $89.30 | 2022-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $88.13 | 2023-2025 | Libtayo |
| Beone Medicines USA, INC. | $82.96 | 2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $79.71 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $73.59 | 2021-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $71.54 | 2024 | Trodelvy |
| Eisai INC. | $70.36 | 2022-2024 | |
| Genzyme Corporation | $67.12 | 2025 | |
| Cti Biopharma Corp. | $58.73 | 2023 | Vonjo |
| Geron Corporation | $47.60 | 2025 | Rytelo |
| Emd Serono, INC. | $46.88 | 2022-2025 | |
| Puma Biotechnology, INC. | $44.64 | 2024-2025 | |
| Seagen INC. | $43.83 | 2022-2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $34.90 | 2023-2025 | |
| Astellas Pharma US INC | $33.74 | 2022-2025 | Vyloy |
| Servier Pharmaceuticals LLC | $33.09 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $31.34 | 2022-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $30.92 | 2023-2024 | Monoferric |
| G1 Therapeutics, INC. | $29.36 | 2023 | Cosela |
| Celgene Corporation | $28.78 | 2022-2024 | Reblozyl |
| Global Blood Therapeutics, INC. | $28.46 | 2021-2022 | |
| Acera Surgical, INC. | $25.56 | 2024 | Restrata Wound Matrix |
| Verastem, INC. | $20.30 | 2025 | Avmapki Fakzynja Co-Pack |
| Stemline Therapeutics INC. | $19.00 | 2025 | Elzonris |
| Legend Biotech USA INC. | $18.07 | 2025 | Carvykti |
| Sumitomo Pharma America, INC. | $17.72 | 2025 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $17.71 | 2025 | Givlaari |
| Aimmune Therapeutics, INC. | $16.85 | 2025 | Zenpep |
| Coherus Oncology, INC. | $16.72 | 2023 | |
| Syndax Pharmaceuticals, INC. | $16.00 | 2025 | Niktimvo |
| Genentech USA, INC. | $15.00 | 2025 | Tecentriq |
| Blueprint Medicines Corporation | $14.86 | 2023 | Ayvakit |
| Kite Pharma, INC. | $13.70 | 2021 | |
| Heron Therapeutics, INC. | $5.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.